AZ Sells EU Rights To Former Jewel In The Crown, Crestor
Grünenthal Paying $320m Upfront
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
